"May 04, 2021 10.28am
Astrazenica's Farxiga claims first SGLT2 kidney disease OK from FDA.
Astrazenica is already seeing sales rocket for its' SGLT2 inhibitor Farxiga in heart failure and is expected to gather even more momentum after claiming FDA approval in CKD.
The US regulator has cleared Farxiga to reduce the risk of kidney damage,end-stage kidney disease,cardiovascular,death and hospitalisation for heart failure in adults with CKD who are at risk of progression."
GR8 news for us ....it shows this space is still a world priority.
"37 million people in the US alone with CKD"
"May 04, 2021 10.28amAstrazenica's Farxiga claims first SGLT2...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.0¢ |
Change
-0.020(2.30%) |
Mkt cap ! $111.3M | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 88.0¢ | 84.5¢ | $104.5K | 121.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12500 | 85.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.0¢ | 2526 | 1 |
View Market Depth
| Last trade - 15.32pm 15/08/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |